DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE

(19)

(11)

EP 1 585 521 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	25.03.2009 Bulletin 2009/13

(45)	Mention of the grant of the patent:
	18.06.2008 Bulletin 2008/25

(21)	Application number: 03813593.5

(22)	Date of filing: 22.12.2003

(51)

International Patent Classification (IPC):

A61K 31/498^(2006.01)
C07D 239/82^(2006.01)
C07D 409/06^(2006.01)
C07D 417/06^(2006.01)
C07D 413/06^(2006.01)
C07D 239/78^(2006.01)
A61P 5/18^(2006.01)

C07D 403/06^(2006.01)
C07D 403/10^(2006.01)
C07D 405/06^(2006.01)
C07D 401/06^(2006.01)
C07D 401/12^(2006.01)
C07C 49/84^(2006.01)

(86)	International application number:
	PCT/EP2003/014741

(87)	International publication number:
	WO 2004/056365 (08.07.2004 Gazette 2004/28)

(54)	DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE DERIVATE VON ARYL-CHINAZOLIN/ARYL-2AMINO-PHENYL-METHANON ZURFÖRDERUNG DER FREISETZUNG VON PARATHORMON DERIVES D'ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

(30)

Priority:

23.12.2002 GB 0230015

(43)	Date of publication of application:
	19.10.2005 Bulletin 2005/42

(60)	Divisional application:
	07110683.5 / 1844780

(73)	Proprietors:
	NOVARTIS AG 4056 Basel (CH) Designated Contracting States: BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR Novartis Pharma GmbH 1230 Wien (AT) Designated Contracting States: AT

(72)	Inventors:
	ALTMANN, Eva CH-4153 Reinach (CH) BEERLI, René CH-4102 Binningen (CH) GERSPACHER, Marc CH-4616 Kappel (CH) RENAUD, Johanne CH-4103 Bottmingen (CH) WEILER, Sven 79539 Lörrach (DE) WIDLER, Leo CH-4142 Muenchenstein (CH)

(74)	Representative: Ott, Johann et al
	Corporate Intellectual Property, Novartis AG 4002 Basel 4002 Basel (CH)

(56)

References cited: :

WO-A-02/24683
CH-A- 612 186
US-A- 3 812 257
US-A- 4 387 223
US-A- 5 856 503

WO-A-20/02102782
GB-A- 1 353 789
US-A- 3 925 548
US-A- 5 773 663
US-B1- 6 211 244

RUSSELL, R. K. ET AL: "Synthesis and renal vasodilator activity of substituted [4-alkyl(aryl)-2-oxoquinazolin-1-yl]alkano ic acids" EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 27, no. 3, 1992, pages 277-284, XP002935850
DATABASE CAPLUS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002280288 retrieved from STN accession no. 1306 Database accession no. 1980:121782 & MIYAGISHI, AKIRA ET ALL: "General pharmaceutical studies on ciproquazone (SL-573) and its metabolites" OYO YAKURI, vol. 18, no. 1, 1979, pages 9-22,
MASAI, NARUHITO ET AL: "Carbon-13 nuclear magnetic resonance studies of anti-inflammatory 2(1H)-quinazolinones" CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 25, no. 11, 1977, pages 3018-3022, XP009000437
DATABASE CAPLUS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002280289 retrieved from STN accession no. 1406 Database accession no. 1982:503745 & S. MARDENTE, C. BICCHI, M.G.NANO: "GLC-ECD determination of 1-(2-hydroxyethyl)-3-hydroxy-7-chloro-1,3- dihydro-5-(O-fluorophenyl)-2H-1,4-benzodoa zepin-2-one (SAS 643) in plasma and urine and identification of its main biotransformation produscts" THERAPEUTIC DRUG MONITORING, vol. 3, no. 4, 1981, pages 351-356,
DATABASE CAPLUS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002280290 retrieved from STN accession no. 1142 Database accession no. 1994:244939 & M.I. JAEDA AT ALL: "Synthesis of some novel 2(1H)-quinazolinones and 2-thioxo analogs from newly synthesized 1-acyl-3-alkoxyphenylureas and tioureas" JOURNAL OF CHEMICAL TECHNOLOGY AND BIOTECHNOLOGY, vol. 58, no. 4, 1993, pages 391-394,
DATABASE CAPLUS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002280291 retrieved from STN accession no. 1277 Database accession no. 1981:461773 & JP 55 143959 A (SHIONOGI AND CO.) 10 November 1980 (1980-11-10)
DATABASE CROSSFIRE BEILSTEIN [Online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002280292 Database accession no. 6810088 & B.BERGER, M.BOLTE: ACTA CRYSTALLOGR. SECT.C: CRYST. STRUCT. COMMUN, vol. 50, 1994, pages 773-775,

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).